NCT03937635 2026-03-02
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
Clinical Trials
20 trialsNCT06212323 2026-02-17
SPOTLIGHT
University of Utah
Recruiting
NCT06140524 2026-01-22
LINKER-MGUS1
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT05640843 2026-01-02
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT06237803 2025-12-03
EMN36
European Myeloma Network B.V.
Recruiting
NCT05312255 2025-12-01
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
Phase NA Recruiting
NCT03717844 2025-11-20
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
Recruiting
NCT06055894 2025-11-13
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT03616483 2025-11-10
The Indiana Myeloma Registry
Indiana University
Recruiting
NCT02726750 2025-10-27
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
Recruiting
NCT05136807 2025-10-27
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
Recruiting
NCT06365060 2025-08-06
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Tufts Medical Center
Recruiting
NCT05841550 2025-08-05
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Oslo University Hospital
Phase 1/2 Recruiting
NCT06762769 2025-08-01
MODIFY
University College, London
Phase 2 Recruiting
NCT06895291 2025-03-30
ONCO-MRI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recruiting
NCT05597345 2025-02-10
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Phase 2 Recruiting
NCT06383143 2024-11-25
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT06183489 2024-10-18
ERASMM
European Myeloma Network B.V.
Phase 2 Recruiting
NCT04731844 2024-07-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Recruiting
NCT05283993 2022-04-25
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Peking University First Hospital
Recruiting